Transcription start sites and epigenetic analysis of the HSD17B10 proximal promoter

BMC Biochemistry

Volumn 14, Issue 1, 2013, Pages

  Yang, Song Yu ^a   Dobkin, Carl ^a   He, Xue Ying ^a   Brown, W Ted ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

CpG island; DNA methylation; HSD10 deficiency; TATA less promoter; X chromosome inactivation

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE 10; 5 METHYLCYTOSINE; GENOMIC DNA; HYDROXYSTEROID; ISOLEUCINE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TISSUE; CODON; CPG ISLAND; DNA FLANKING REGION; EPIGENETICS; EXON; HUMAN; HUMAN TISSUE; PROMOTER REGION; PYROSEQUENCING; TRANSCRIPTION INITIATION SITE; X CHROMOSOME INACTIVATION;

3-HYDROXYACYL COA DEHYDROGENASES; 5-METHYLCYTOSINE; BASE SEQUENCE; CHROMOSOMES, HUMAN, X; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EXONS; FEMALE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; TRANSCRIPTION INITIATION SITE;

EID: 84879828505     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-14-17     Document Type: Article

References (38)

1. HSD17B10: A gene involved in cognitive function through metabolism of isoleucine and neuroactive steroids. Yang SY, He XY, Miller D, Mol Genet Metab 2007 92 36 42 10.1016/j.ymgme.2007.06.001 17618155 (Pubitemid 47361893)
2. Roles of type 10 17beta-hydroxysteroid dehydrogenase in intracrinology and metabolism of isoleucine and fatty acids. He XY, Yang SY, Endoc Metab Immun Dis-Drug, Targets 2006 6 95 102 10.2174/187153006776056639
3. Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase. Yang SY, He XY, Schulz H, Trends Endocrinol Metab 2005 16 167 175 10.1016/j.tem.2005.03.006 15860413 (Pubitemid 40603096)
4. RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Holzmann J, Frank P, Löffler E, Bennett KL, Gerner C, Rossmanith W, Cell 2008 135 462 474 10.1016/j.cell.2008. 09.013 18984158
5. Binding of amyloid β-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implication for apoptosis in Alzheimer's disease. Oppermann UC, Salim S, Tjernberg LO, Terenius L, Jornvall H, FEBS Lett 1999 451 238 242 10.1016/S0014-5793(99)00586-4 10371197 (Pubitemid 29243784)
6. Estrogen receptor alpha interacts with 17beta-hydroxysteroid dehydrogenase type 10 in mitochondria. Jazbutyte V, Kehl F, Neyses L, Pelzer T, Biochem Biophys Res Commun 2009 384 450 454 10.1016/j.bbrc.2009.04.139 19422801
7. Mental retardation linked to mutations in the HSD17B10 gene interefering with neurosteroid and isoleucine metabolism. Yang S-Y, He X-Y, Olpin SE, Sutton VR, McMenamin J, Philipp M, Denman RB, Malik M, Proc Natl Acad Sci USA 2009 106 14820 14824 10.1073/pnas.0902377106 19706438
8. A novel mutation in the HSD17B10 gene of a 10-year-old boy with refractory epilepsy, chreoathetosis and learning disability. Seaver LH, He XY, Abe K, Cowan T, Enns GM, Sweetman L, Lee S, Malik M, Yang SY, PLoS One 2011 6 27348 10.1371/journal.pone.0027348 22132097
9. The reduced expression of the HADH2 protein causes X-linked mental retardation, choreoathetosis, and abnormal behavior. Lenski C, Kooy RF, Reyniers E, Loessner D, Wanders RJA, Winnepenninckx B, Hellebrand H, Engert S, Schwartz CE, Meindl A, Ramser J, Am J Hum Genet 2007 80 372 377 10.1086/511527 17236142 (Pubitemid 46175685)
10. Role of type 10 17 beta-hydroxysteroid dehydrogenase in the pathogenesis of Alzheimer's disease. Yang SY, He XY, Neuropathology and Genetics of Dementia New York: Kluwer Academic, Tolnay M, Probst A, 2001 101 110
11. Enhanced levels of mitochondrial enzyme 17beta-hydroxysteroid dehydrogenase type 10 in patients with Alzheimer disease and multiple sclerosis. Kristofiková Z, Bocková M, Hegnerová K, Bartos A, Klaschka J, Rícný J, Rípová D, Homola J, Mol Biosyst 2009 5 1174 1179 10.1039/b904799a 19756307
12. Type 10 17beta-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of γ-aminobutyric acid type A receptors. He XY, Wegiel J, Yang YZ, Pullarkat R, Schulz H, Yang SY, Mol Cell Endocrinol 2005 229 111 117 10.1016/j.mce.2004.08.011 15607535 (Pubitemid 40018089)
13. Amyloid β-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress. Yan SD, Zhu Y, Stern ED, Hwang YC, Hori O, Ogawa S, Frosch MP, Conolly ES Jr, McTaggert R, Pinsky DJ, Clarke S, Stern DM, Ramasamy R, J Biol Chem 2000 275 27100 27109 10869339
14. Changes of the HSD17B10 gene expression levels in ulcerative colitis. He XY, Yang YX, Yang SY, Inflamm Bowel Dis 2013 19 23 E24 10.1002/ibd.22882 22271489
15. Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit F, Rutgeerts P, Verbeke K, Inflamm Bowel Dis 2012 18 1127 1136 10.1002/ibd.21894 21987487
16. Does the HSD17B10 gene escape from X-inactivation? He XY, Dobkin C, Yang SY, Eur J Hum Genet 2011 2011 19 123 124
17. A human brain L-3-hydroxyacyl-CoA dehydrogenase is identical with an amyloid β-peptide binding protein involved in Alzheimers disease. He XY, Schulz H, Yang SY, J Biol Chem 1998 273 10741 10746 10.1074/jbc.273.17.10741 9553139 (Pubitemid 28227690)
18. z-§ssup§32§esup§P labeling of RNA and DNA fragments. Chaconas G, van der Sande JH, Methods Enzymol 1980 65 75 85 6154877
19. Nucleotide sequence of the promoter and fadB gene of the fadBA operon and primary structure of the multifunctional fatty acid oxidation protein from E. coli. He Yang XY, Schulz H, Elzinga M, Yang SY, Biochemistry 1991 30 6788 6795 10.1021/bi00241a023 1712230
20. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragil X syndrome. Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, Loring JF, Haggarty SJ, PLoS One 2011 6 26203 10.1371/journal.pone.0026203 22022567
21. The ENCODE project: implication for psychiatric genetics. Kavanagh DH, Dwyer S, O'Dovovan MC, Owen MJ, Mol Psychiatry 2013 18 540 542 10.1038/mp.2013.13 23478746
22. Hydroxysteroid (17β) dehydrogenase X in human health and disease. Yang SY, He XY, Miller D, Mol Cell Endocrinol 2011 343 1 6 10.1016/j.mce.2011. 06.011 21708223
23. Integrated view on 17beta-hydroxysteroid dehydrogenases. Moeller G, Adamski J, Mol Cell Endocrinol 2009 301 7 19 10.1016/j.mce.2008.10.040 19027824
24. Type 10 17β-hydroxysteroid dehydrogenase expression is regulated by C/EBPβ in HepG2 cells. Rotenin M, Villar J, Celay J, Encio I, J Steroid Biochem Mol Biol 2010 122 164 171 10.1016/j.jsbmb.2010.07.003 20638476
25. Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. Thorsen K, Schepeler T, Oster B, Rasmussen MH, Vang S, Wang K, Hansen KQ, Lamy P, Pedersen JS, Eller A, Mansilla F, Laurila K, Wiuf C, Laurberg S, Dyrskjøt L, Ørntoft TF, Andersen CL, BMC Genomics 2011 12 505 10.1186/1471-2164-12- 505 21999571
26. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schübeler D, Nature Genet 2007 39 457 466 10.1038/ng1990 17334365 (Pubitemid 46514772)
27. Chromosome-wide DNA methylation analysis predicts human tissue-specific X inactivation. Cotton AM, Lam L, Affleck JG, Wilson IM, Penaherrera MS, McFadden DE, Kobor MS, Lam WL, Robinson WP, Brown CJ, Hum Genet 2011 130 187 201 10.1007/s00439-011-1007-8 21597963
28. Chromosomal basis of X chromosome inactivation: identification of a multigene domain in Xp11.21-p. 11.22 that escapes X inactivation. Miller AP, Willard HF, Proc Natl Acad Sci USA 1998 95 8709 8714 10.1073/pnas.95.15.8709 9671743 (Pubitemid 28350553)
29. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Carrel L, Willard HF, Nature 2005 434 400 404 10.1038/nature03479 15772666 (Pubitemid 40469185)
30. DNA methylation profiles of human active and inactive X chromosomes. Sharp AJ, Stathaki E, Migiavacca E, Brahmachary M, Montgomery SB, Genome Res 2011 21 1592 1600 10.1101/gr.112680.110 21862626
31. X chromosome-wide analyses of genomic DNA methylation states and gene expression in male and female neutrophis. Yasukochi Y, Maruyama O, Mahaian MC, Padden C, Euskirchen GM, Proc Natl Acad Sci USA 2010 107 3704 3709 10.1073/pnas.0914812107 20133578
32. MethylomeDB: a database of DNA methylation profiles of the brain. Xin Y, Chanrion B, O'Donnell AH, Milekic M, Costa R, Ge Y, Haghighi FG, Nucleic Acids Res 2012 40 1245 D1249 10.1093/nar/gkr1193 22140101
33. X-inactivation of HSD17B10 revealed by cDNA analysis in two female patients with 17β-hydroxysteroid dehydrogenase 10 deficiency. Garciar-Villoria J, Gort L, Madrigal I, Fons C, Fernandez C, Navarro-Sastre A, Milà M, Briones P, García-Cazorla A, Campistol J, Ribes A, Eur J Hum Genet 2010 18 1353 1356 10.1038/ejhg.2010.118 20664630
34. Reply to He et al. Garciar-Villoria J, Gort L, Madrigal I, Fons C, Fernandez C, Navarro-Sastre A, Milà M, Briones P, García-Cazorla A, Campistol J, Ribes A, Eur J Hum Genet 2011 19 124 10.1038/ejhg.2010.194
35. Genes that escape from X inactivation. Berletch JB, Yang F, Xu J, Carrel L, Disteche CM, Hum Genet 2011 130 237 245 10.1007/s00439-011-1011-z 21614513
36. A 5-methylcytosine hotspot responsible for the prevalent HSD17B10 mutation. Yang SY, Dobkin C, He XY, Phillip M, Brown WT, Gene 2013 515 380 384 10.1016/j.gene.2012.12.064 23266819
37. Clinical variability in 3-hydroxy-2-methylbutyryl-CoA dehydrogenase deficiency. Ensenauer R, Niederhoff H, Ruiter JP, Wanders RJ, Schwab KO, Brandis M, Lehnert W, Ann Neurol 2002 51 656 659 10.1002/ana.10169 12112118 (Pubitemid 34438711)
38. Study of patients and carriers with 2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency: difficulties in the diagnosis. Garciar-Villoria J, Navarro-Sastre A, Fons C, Pérez-Cerdá C, Baldellou A, Fuentes-Castelló MA, González I, Hernández-Gonzalez A, Fernández C, Campistol J, Delpiccolo C, Cortés N, Messeguer A, Briones P, Ribes A, Clin Biochem 2009 42 27 33 10.1016/j.clinbiochem.2008.10.006 18996107